These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 37608622)

  • 1. Even effective drugs require adequately powered trials: Systemic bevacizumab in hereditary hemorrhagic telangiectasia.
    Al-Samkari H
    J Intern Med; 2023 Dec; 294(6):684-686. PubMed ID: 37608622
    [No Abstract]   [Full Text] [Related]  

  • 2. Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia : A case report.
    Huemer F; Dejaco M; Grabmer C; Melchardt T; Neureiter D; Mayer G; Egle A; Greil R; Weiss L
    Wien Klin Wochenschr; 2017 Feb; 129(3-4):141-144. PubMed ID: 27878613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab as a treatment for hereditary hemorrhagic telangiectasia in children: a case report.
    Ospina FE; Echeverri A; Posso-Osorio I; Jaimes L; Gutierrez J; Tobón GJ
    Colomb Med (Cali); 2017 Jun; 48(2):88-93. PubMed ID: 29021642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aflibercept for Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia: A Case Report.
    Villanueva B; Iriarte A; Torres-Iglesias R; Muñoz Bolaño M; Cerdà P; Riera-Mestre A
    Medicina (Kaunas); 2023 Aug; 59(9):. PubMed ID: 37763652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers.
    Al-Samkari H; Albitar HA; Olitsky SE; Clancy MS; Iyer VN
    Orphanet J Rare Dis; 2019 Nov; 14(1):256. PubMed ID: 31727111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bevacizumab: a new success in hereditary hemorrhagic telangiectasia].
    Bennesser Alaoui H; Lehraiki M; Hamaz S; El Attar N; Fakhreddine N; Serraj K
    Rev Med Interne; 2015 Sep; 36(9):623-5. PubMed ID: 25595875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ELLIPSE Study: a Phase 1 study evaluating the tolerance of bevacizumab nasal spray in the treatment of epistaxis in hereditary hemorrhagic telangiectasia.
    Dupuis-Girod S; Ambrun A; Decullier E; Samson G; Roux A; Fargeton AE; Rioufol C; Schwiertz V; Disant F; Chapuis F; Donazzolo Y; Paintaud G; Edery P; Faure F
    MAbs; 2014; 6(3):794-9. PubMed ID: 24481211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab as Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Literature Review.
    Kini SD; Yiu DW; Weisberg RA; Davila JF; Chelius DC
    Ann Otol Rhinol Laryngol; 2019 May; 128(5):467-471. PubMed ID: 30693788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blessing for the bleeder: bevacizumab in hereditary hemorrhagic telangiectasia.
    Epperla N; Hocking W
    Clin Med Res; 2015 Mar; 13(1):32-5. PubMed ID: 24667223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful therapy with bevacizumab in a case of hereditary hemorrhagic telangiectasia.
    Kochanowski J; Sobieszczańska M; Tubek S; Żurek M; Pawełczak J
    Hum Vaccin Immunother; 2015; 11(3):680-1. PubMed ID: 25839219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia: An Evidence-based Review.
    Halderman AA; Ryan MW; Marple BF; Sindwani R; Reh DD; Poetker DM
    Am J Rhinol Allergy; 2018 Jul; 32(4):258-268. PubMed ID: 29745243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hereditary hemorrhagic telangiectasia (OslerWeberRendu syndrome) - Part II. Pharmacological therapy and international guidelines for the therapy 2020.
    Adam Z; Brančiková D; Romanová G; Pour L; Krejčí M; König J; Nebeský T; Adamová Z; Štork M; Krejčí M; Ševčíková S; Eid M; Sandecká V; Král Z
    Vnitr Lek; 2021; 67(7):419-424. PubMed ID: 35459360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic Bevacizumab for Hereditary Hemorrhagic Telangiectasia: Considerations from Observational Studies.
    Al-Samkari H
    Otolaryngol Head Neck Surg; 2019 Feb; 160(2):368. PubMed ID: 30798765
    [No Abstract]   [Full Text] [Related]  

  • 14. Pazopanib effective for bevacizumab-unresponsive epistaxis in hereditary hemorrhagic telangiectasia.
    Parambil JG; Woodard TD; Koc ON
    Laryngoscope; 2018 Oct; 128(10):2234-2236. PubMed ID: 29451965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High output cardiac failure in 3 patients with hereditary hemorrhagic telangiectasia and hepatic vascular malformations, evaluation of treatment.
    Olsen LB; Kjeldsen AD; Poulsen MK; Kjeldsen J; Fialla AD
    Orphanet J Rare Dis; 2020 Nov; 15(1):334. PubMed ID: 33243256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to "Systemic Bevacizumab for Hereditary Hemorrhagic Telangiectasia: Considerations from Observational Studies".
    Hsu YP; Hsu CW; Chen C
    Otolaryngol Head Neck Surg; 2019 Feb; 160(2):369-370. PubMed ID: 30798740
    [No Abstract]   [Full Text] [Related]  

  • 17. A lack of race and ethnicity data in the treatment of hereditary hemorrhagic telangiectasia: a systematic review of intravenous bevacizumab efficacy.
    Galiatsatos P; Wilson C; O'Brien J; Gong AJ; Angiolillo D; Johnson J; Myers C; Strout S; Mathai S; Robinson G; Rowan NR; Weiss CR
    Orphanet J Rare Dis; 2022 Jun; 17(1):220. PubMed ID: 35698080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia.
    Azzopardi N; Dupuis-Girod S; Ternant D; Fargeton AE; Ginon I; Faure F; Decullier E; Roux A; Carette MF; Gilbert-Dussardier B; Hatron PY; Lacombe P; Leguy-Seguin V; Rivière S; Corre R; Bailly S; Paintaud G
    MAbs; 2015; 7(3):630-7. PubMed ID: 25751241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous and topical intranasal bevacizumab (Avastin) in hereditary hemorrhagic telangiectasia.
    Brinkerhoff BT; Choong NW; Treisman JS; Poetker DM
    Am J Otolaryngol; 2012; 33(3):349-51. PubMed ID: 21917353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia.
    Al-Samkari H; Kritharis A; Rodriguez-Lopez JM; Kuter DJ
    J Intern Med; 2019 Feb; 285(2):223-231. PubMed ID: 30191646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.